So basically, we have known that there is a relationship between lipids and Alzheimer’s for a long time. And one way to test this is to make lipoprotein particles. In this abstract, we present the findings of a peptide called CS6253 that induces the formation of HDL-like particles. These are good cholesterol-containing particles. It efficiently binds to ABCA1 to make these particles. And we have shown that in preclinical animal models, it had favorable effects...
So basically, we have known that there is a relationship between lipids and Alzheimer’s for a long time. And one way to test this is to make lipoprotein particles. In this abstract, we present the findings of a peptide called CS6253 that induces the formation of HDL-like particles. These are good cholesterol-containing particles. It efficiently binds to ABCA1 to make these particles. And we have shown that in preclinical animal models, it had favorable effects. Then it passed all the safety testings in mice, rodents, monkeys. And finally, we show now Phase I human study findings in which it was safe. And not only that, it mimicked the findings in monkeys where we increased APOE and showed some signs in a very small population that A-beta might be changing in plasma. Just to note that CS6253 does not cross into the brain or does not cross the blood-brain barrier. So these are peripheral effects.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
